Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis

被引:63
作者
Jones, Paul W. [1 ]
Donohue, James F. [2 ]
Nedelman, Jerry [3 ]
Pascoe, Steve [4 ]
Pinault, Gregory [4 ]
Lassen, Cheryl [5 ]
机构
[1] St Georges Univ London, Div Clin Sci, London, England
[2] Univ N Carolina, Sch Med, Div Pulm & Crit Care Med, Chapel Hill, NC USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharma AG, Basel, Switzerland
[5] Novartis Horsham Res Ctr, Horsham, W Sussex, England
关键词
COPD; spirometry; FEV1; health status; dyspnoea; INHALED BRONCHODILATORS; RANDOMIZED-TRIALS; HEALTH-STATUS; COPD; INDACATEROL; EFFICACY; EXACERBATIONS; FLUTICASONE; PROPIONATE; SALMETEROL;
D O I
10.1186/1465-9921-12-161
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Relationships between improvements in lung function and other clinical outcomes in chronic obstructive pulmonary disease (COPD) are not documented extensively. We examined whether changes in trough forced expiratory volume in 1 second (FEV1) are correlated with changes in patient-reported outcomes. Methods: Pooled data from three indacaterol studies (n = 3313) were analysed. Means and responder rates for outcomes including change from baseline in Transition Dyspnoea Index (TDI), St. George's Respiratory Questionnaire (SGRQ) scores (at 12, 26 and 52 weeks), and COPD exacerbation frequency (rate/year) were tabulated across categories of Delta FEV1. Also, generalised linear modelling was performed adjusting for covariates such as baseline severity and inhaled corticosteroid use. Results: With increasing positive Delta FEV1, TDI and Delta SGRQ improved at all timepoints, exacerbation rate over the study duration declined (P < 0.001). Individual-level correlations were 0.03-0.18, but cohort-level correlations were 0.79-0.95. At 26 weeks, a 100 ml increase in FEV1 was associated with improved TDI (0.46 units), Delta SGRQ (1.3-1.9 points) and exacerbation rate (12% decrease). Overall, adjustments for baseline covariates had little impact on the relationship between Delta FEV1 and outcomes. Conclusions: These results suggest that larger improvements in FEV1 are likely to be associated with larger patient-reported benefits across a range of clinical outcomes.
引用
收藏
页数:10
相关论文
共 31 条
[1]   Impact of chronic obstructive pulmonary disease on activities of daily living:: Results of the EIME Multicenter Study [J].
Alvarez-Gutierrez, Francisco Javier ;
Miravitlles, Marc ;
Calle, Miriam ;
Gobartt, Elena ;
Lopez, Francisco ;
Martin, Antonio .
ARCHIVOS DE BRONCONEUMOLOGIA, 2007, 43 (02) :64-72
[2]  
Anzueto A, 2009, Int J Chron Obstruct Pulmon Dis, V4, P245
[3]   Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456
[4]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[5]   Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD [J].
Dahl, Ronald ;
Chung, Kian Fan ;
Buhl, Roland ;
Magnussen, Helgo ;
Nonikov, Vladimir ;
Jack, Damon ;
Bleasdale, Patricia ;
Owen, Roger ;
Higgins, Mark ;
Kramer, Benjamin .
THORAX, 2010, 65 (06) :473-479
[6]   Sex differences in mortality in patients with COPD [J].
de Torres, J. P. ;
Cote, C. G. ;
Lopez, M. V. ;
Casanova, C. ;
Diaz, O. ;
Marin, J. M. ;
Pinto-Plata, V. ;
de Oca, M. M. ;
Nekach, H. ;
Dordelly, L. J. ;
Aguirre-Jaime, A. ;
Celli, B. R. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (03) :528-535
[7]   Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD [J].
Di Marco, F ;
Milic-Emili, J ;
Boveri, B ;
Carlucci, P ;
Santus, P ;
Casanova, F ;
Cazzola, M ;
Centanni, S .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (01) :86-94
[8]  
Donohue James F, 2005, COPD, V2, P111
[9]   Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease Indacaterol Versus Tiotropium [J].
Donohue, James F. ;
Fogarty, Charles ;
Lotvall, Jan ;
Mahler, Donald A. ;
Worth, Heinrich ;
Yorgancioglu, Arzu ;
Iqbal, Amir ;
Swales, James ;
Owen, Roger ;
Higgins, Mark ;
Kramer, Benjamin .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (02) :155-162
[10]   Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study [J].
Feldman, Gregory ;
Siler, Thomas ;
Prasad, Niyati ;
Jack, Damon ;
Piggott, Simon ;
Owen, Roger ;
Higgins, Mark ;
Kramer, Benjamin .
BMC PULMONARY MEDICINE, 2010, 10